96 related articles for article (PubMed ID: 3837504)
1. Continuous ambulatory EEG monitoring following desferrioxamine (DFO) i.v. infusion.
Poignet JL; Monge MF; Ciancioni C; Mikol F; Naret C; Delons S; Man NK
Trans Am Soc Artif Intern Organs; 1985; 31():546-51. PubMed ID: 3837504
[No Abstract] [Full Text] [Related]
2. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
Ciancioni C; Poignet JL; Mauras Y; Panthier G; Delons S; Allain P; Man NK
Trans Am Soc Artif Intern Organs; 1984; 30():479-82. PubMed ID: 6533925
[No Abstract] [Full Text] [Related]
3. Desferrioxamine in the treatment of aluminum overload.
Ackrill P; Day JP
Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
[TBL] [Abstract][Full Text] [Related]
4. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
Roodhooft AM; van de Vyver FL; D'Haese PC; van Acker KJ; Visser WJ; de Broe ME
Clin Nephrol; 1987 Sep; 28(3):125-9. PubMed ID: 3665205
[TBL] [Abstract][Full Text] [Related]
5. Effect of desferrioxamine infusion on red blood cell aluminum.
Umeda M; Umimoto K; Tsurusaki K; Izumi N; Kishimoto T; Maekawa M
ASAIO Trans; 1988; 34(3):297-9. PubMed ID: 3196524
[TBL] [Abstract][Full Text] [Related]
6. The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature.
Boelaert JR; van Roost GF; Vergauwe PL; Verbanck JJ; de Vroey C; Segaert MF
Clin Nephrol; 1988 May; 29(5):261-6. PubMed ID: 3293856
[TBL] [Abstract][Full Text] [Related]
7. Prevention and treatment of aluminum intoxication in chronic renal failure.
Simon P; Allain P; Ang KS; Cam G; Mauras Y
Adv Nephrol Necker Hosp; 1985; 14():439-78. PubMed ID: 3919543
[No Abstract] [Full Text] [Related]
8. Correlation between serum aluminum concentration and signs of encephalopathy in a large population of patients dialyzed with aluminum-free fluids.
Rovelli E; Luciani L; Pagani C; Albonico C; Colleoni N; D'Amico G
Clin Nephrol; 1988 Jun; 29(6):294-8. PubMed ID: 3396232
[TBL] [Abstract][Full Text] [Related]
9. Desferrioxamine infusion can modify EEG tracing in haemodialysed patients.
Brancaccio D; Avanzini G; Padovese P; Gallieni M; Franceschetti S; Panzica F; Anelli A; Colantonio G; Martinelli D; Bugiani O
Nephrol Dial Transplant; 1991; 6(4):264-8. PubMed ID: 1881580
[TBL] [Abstract][Full Text] [Related]
10. [Successful treatment of progressive dialysis encephalopathy. Case report].
Weiland P; Köhler M; Glatzel E
Z Urol Nephrol; 1985 Jul; 78(7):387-93. PubMed ID: 4050157
[TBL] [Abstract][Full Text] [Related]
11. [Severe ocular toxicity of desferrioxamine in the hemodialyzed patient].
Bournerias F; Monnier N; Dufier JL; Réveillaud RJ
Nephrologie; 1987; 8(1):27-9. PubMed ID: 3587485
[TBL] [Abstract][Full Text] [Related]
12. Use of a desferrioxamine "microdose" to chelate aluminum in hemodialysis patients.
Jorge C; Gil C; Possante M; Catarino MC; Cruz A; Andrade R; Teixeira R; Santos N; Ferreira A
Clin Nephrol; 1999 Nov; 52(5):335-6. PubMed ID: 10585000
[No Abstract] [Full Text] [Related]
13. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
Lillevang ST; Pedersen FB
Nephrol Dial Transplant; 1989; 4(7):676. PubMed ID: 2510071
[No Abstract] [Full Text] [Related]
14. Desferrioxamine and hemofiltration for aluminum removal in patients on regular dialysis treatment.
Segoloni G; Canavese G; D'Amicone M; Rubino GF; Scansetti G; Lamon S; Talarico S; Luda E; Vercellone A
Clin Nephrol; 1983 Aug; 20(2):105-8. PubMed ID: 6616975
[No Abstract] [Full Text] [Related]
15. Role of desferrioxamine in the treatment of dialysis encephalopathy.
Ackrill P; Ralston AJ; Day JP
Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985
[No Abstract] [Full Text] [Related]
16. Red blood cell aluminum in patients with renal failure and effect of desferrioxamine infusion.
Umeda M; Tsurusaki K; Kamikawa S; Izumi N; Yasumoto R; Kishimoto T; Maekawa M
Blood Purif; 1990; 8(5):295-300. PubMed ID: 2091689
[TBL] [Abstract][Full Text] [Related]
17. Changes of metal concentrations in blood and peritoneal dialysate during long-term desferrioxamine B therapy.
Romero RA; Salgado O; Elejalde LE; Rodríguez-Iturbe B; Tahán JE
Transplant Proc; 1996 Dec; 28(6):3385-7. PubMed ID: 8962321
[No Abstract] [Full Text] [Related]
18. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
Graf H; Stummvoll HK; Meisinger V
Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995
[TBL] [Abstract][Full Text] [Related]
19. Effect of desferrioxamine on aluminum kinetics during hemodialysis.
Stummvoll HK; Graf H; Meisinger V
Miner Electrolyte Metab; 1984; 10(4):263-6. PubMed ID: 6749073
[TBL] [Abstract][Full Text] [Related]
20. Irreversible ocular toxicity from single "challenge" dose of deferoxamine.
Bene C; Manzler A; Bene D; Kranias G
Clin Nephrol; 1989 Jan; 31(1):45-8. PubMed ID: 2783668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
